Gilead eyes Kymera’s ‘adhesive’ cancer drug in $750m deal
Fresh off a regulatory victory for a new HIV product, Gilead is shifting focus to the oncology space – signing …
Post
-
-
Navigating uncertainty: the future of vaccine oversight amid CDC firings
In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed …
-
How will RFK Jr’s American dream for vaccines play out?
In an interview with Fox News in 2023, Robert F Kennedy (RFK) Jr said: “Autism comes from vaccines.” This claim …
-
EHDS regulation will depend on strong patient confidence
European residents must be fully informed to properly trust the incoming European Health Data Space (EHDS) regulation if it is …
-
US FDA approves GSK’s Benlysta autoinjector for lupus nephritis
The US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years …
-
GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion
The US Food and Drug Administration (FDA) has expanded the indications of an imaging agent developed by GE HealthCare, which …
-
Medera and Novoheart collaborate on mini-heart models for HLHS
Medera and its subsidiary Novoheart have collaborated with scientists at the University of California San Diego School of Medicine and …
-
Alzheimer’s R&D resurgence driven by $16.8bn in acquisitions in 2025YTD
Biopharmaceutical companies developing Alzheimer’s disease innovator drugs have witnessed a flurry of acquisitions over the past few years, surging in …
-
Revolution Medicines partners Royalty Pharma on $2bn funding
Revolution Medicines has partnered Royalty Pharma for $2bn in flexible funding to support the independent worldwide development and commercialisation strategy …
-
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults …
-
Pharmaceutical Technology Excellence Awards 2025: i3 Membrane
ii3 Membrane has won three awards in the Innovation, Research and Development (R&D), and Environmental categories in the 2025 Pharmaceutical …
-
Overcoming technical challenges in gene therapy product fill-finish operations
Gene therapy holds transformative potential in treating a wide range of diseases—from cancer and genetic disorders to infectious diseases. While …
-
Zambon gains Chinese regulatory authority approval for Fluimucil IV
Zambon Pharma has received approval from Chinese regulatory authorities and launched Fluimucil (N-acetylcysteine) intravenous (IV) formulation in the country. The development …
-
Navamedic signs agreement to acquire dne pharma
Navamedic has signed an agreement for the acquisition of Norwegian company dne pharma in a Nkr225m ($22m) deal. This acquisition marks …
-
Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug
Novo Nordisk has terminated a collaboration agreement with Hims & Hers, accusing the telehealth company of "failing to adhere to …
